1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Sandoz Gains An Edge With High-Concentration US Humira Biosimilar

Hyrimoz Version Of Adalimumab Approved By FDA In Citrate-Free 100mg/ml Form

 
• By Dave Wallace

Sandoz has gained a potential advantage ahead of being part of a second wave of Humira biosimilar competition hitting the US, with the firm obtaining FDA approval for its Hyrimoz version of adalimumab in a citrate-free high-concentration formulation.

High low 3D words
Sandoz now has FDA approval for both high and low strength adalimumab • Source: Shutterstock

With a second wave of Humira (adalimumab) rivals set to hit the US in just a few months time, Sandoz has gained US Food and Drug Administration approval for a citrate-free, high-concentration 100mg/ml version of its already approved Hyrimoz (adalimumab-adaz) biosimilar.

Following Amgen’s launch of its Amjevita (adalimumab-atto) 50mg/ml biosimilar at the end of January (Also see "Amgen Delivers On...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Kashiv’s Xolair Biosimilar Nears US And EU Filings As Phase III Data Reports

 
• By Urtė Fultinavičiūtė

Following the filing acceptance in the UK earlier this year, Kashiv and its three commercial musketeers – Alvotech, Advanz Pharma, and Amneal – are getting ready for applications in the US and Europe.

Formycon Signs US-Canada Deal With Valorum Biologics For Eylea Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon continues to expand its partnership network with a fresh deal for its aflibercept biosimilar in the US and Canada. At the same time, the firm has received a high demand for its corporate bonds, leading to early offering closure.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)

Biocon Agreement Provides Multiple Oncology Biosimilars To Malaysian Cancer NGO

 
• By Dean Rudge

Biocon Biologics will look to combine its “scientific expertise with the National Cancer Society of Malaysia’s strong community outreach and patient support network,” after signing striking up a partnership with the NGO providing for supply of three biosimilars.

More from Products

Biocon Agreement Provides Multiple Oncology Biosimilars To Malaysian Cancer NGO

 
• By Dean Rudge

Biocon Biologics will look to combine its “scientific expertise with the National Cancer Society of Malaysia’s strong community outreach and patient support network,” after signing striking up a partnership with the NGO providing for supply of three biosimilars.

Cigna Claims BMS Tied Revlimid Settlements to Pomalyst ‘Pay-for-Delay’ Scheme

 
• By Dean Rudge

Among other schemes, Cigna alleges that Celgene and parent Bristol Myers Squibb “paid” generic challengers – via lucrative Revlimid profit-sharing agreements – to delay generic market entry for Pomalyst until 2026, unlawfully extending their monopoly and overcharging purchasers.

US Supreme Court Requests Solicitor General Input On Hikma Skinny Label Case

 
• By Dean Rudge

The US Supreme Court is seeking a brief “expressing the views of the United States,” following the US Federal Circuit’s decision to reopen Amarin’s claim of induced infringement against Hikma relating to its ‘skinny-label’ generic Vascepa (icosapent ethyl) product.